234 related articles for article (PubMed ID: 27496055)
1. A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease.
Ruseckaite R; Beckmann K; O'Callaghan M; Roder D; Moretti K; Millar J; Evans S
BMC Cancer; 2016 Aug; 16():607. PubMed ID: 27496055
[TBL] [Abstract][Full Text] [Related]
2. Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset.
Ruseckaite R; Beckmann K; O'Callaghan M; Roder D; Moretti K; Zalcberg J; Millar J; Evans S
BMC Res Notes; 2016 Jan; 9():37. PubMed ID: 26801762
[TBL] [Abstract][Full Text] [Related]
3. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry.
Weerakoon M; Papa N; Lawrentschuk N; Evans S; Millar J; Frydenberg M; Bolton D; Murphy DG
BJU Int; 2015 Apr; 115 Suppl 5():50-6. PubMed ID: 25601201
[TBL] [Abstract][Full Text] [Related]
4. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
[TBL] [Abstract][Full Text] [Related]
5. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations.
Jeong CW; Washington SL; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
Eur Urol; 2020 Sep; 78(3):335-344. PubMed ID: 31980309
[TBL] [Abstract][Full Text] [Related]
6. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
7. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia.
Ruseckaite R; Sampurno F; Millar J; Frydenberg M; Evans S
BMC Urol; 2016 Sep; 16(1):54. PubMed ID: 27589955
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
[TBL] [Abstract][Full Text] [Related]
10. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.
Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Xie L; Meadows E; Danella J; Cher ML
BMC Urol; 2018 Jun; 18(1):55. PubMed ID: 29866100
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
12. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
14. Trends in Conservative Management for Low-risk Prostate Cancer in a Population-based Cohort of Australian Men Diagnosed Between 2009 and 2016.
Ong WL; Evans SM; Evans M; Tacey M; Dodds L; Kearns P; Milne RL; Foroudi F; Millar J
Eur Urol Oncol; 2021 Apr; 4(2):319-322. PubMed ID: 31411964
[TBL] [Abstract][Full Text] [Related]
15. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic characteristics of lethal prostate cancer.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Brasso K; Vainer B; Iversen P
Eur J Cancer; 2017 Oct; 84():18-26. PubMed ID: 28779631
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria.
Evans MA; Millar JL; Earnest A; Frydenberg M; Davis ID; Murphy DG; Kearns PA; Evans SM
Med J Aust; 2018 Jun; 208(10):439-443. PubMed ID: 29793403
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
